05781nam 2201477z- 450 991055754430332120231214133639.0(CKB)5400000000044164(oapen)https://directory.doabooks.org/handle/20.500.12854/76594(EXLCZ)99540000000004416420202201d2021 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierPreclinical Evaluation of Lipid-Based NanosystemsBasel, SwitzerlandMDPI - Multidisciplinary Digital Publishing Institute20211 electronic resource (351 p.)3-0365-1550-X 3-0365-1549-6 The use of lipid-based nanosystems, including lipid nanoparticles (solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)), nanoemulsions, and liposomes, among others, is widespread. Several researchers have described the advantages of different applications of these nanosystems. For instance, they can increase the targeting and bioavailability of drugs, improving therapeutic effects. Their use in the cosmetic field is also promising, owing to their moisturizing properties and ability to protect labile cosmetic actives. Thus, it is surprising that only a few lipid-based nanosystems have reached the market. This can be explained by the strict regulatory requirements of medicines and the occurrence of unexpected in vivo failure, which highlights the need to conduct more preclinical studies.Current research is focused on testing the in vitro, ex vivo, and in vivo efficacy of lipid-based nanosystems to predict their clinical performance. However, there is a lack of method validation, which compromises the comparison between different studies.This book brings together the latest research and reviews that report on in vitro, ex vivo, and in vivo preclinical studies using lipid-based nanosystems. Readers can find up-to-date information on the most common experiments performed to predict the clinical behavior of lipid-based nanosystems. A series of 15 research articles and a review are presented, with authors from 15 different countries, which demonstrates the universality of the investigations that have been carried out in this area.Technology: general issuesbicsscnanostructured lipid carriers (NLC)formulation optimizationrivastigminequality by design (QbD)nasal routenose-to-brainN-alkylisatinliposomeurokinase plasminogen activatorPAI-2SerpinB2breast cancerliposomestarget delivery nanosystemFZD10 proteincolon cancer therapysupersaturationsilica-lipid hybridspray dryinglipolysislipid-based formulationfenofibratemesoporous silicaoral drug deliveryhyaluronic aciddrug releaselight activationstabilitymobilitybiocoronadissolution enhancementphospholipidssolid dosage formsporous microparticlesnanoemulsion(s)phase-behaviorDoED-optimal designvegetable oilsnon-ionic surfactantsefavirenzflaxseed oilnanostructured lipid carriersnanocarrierdocohexaenoic acidneuroprotectionneuroinflammationfluconazoleBox‒Behnken designnanotransfersomeulcer indexzone of inhibitionrheological behaviorex vivo permeationnanomedicinecancerdoxorubicinmelanomadrug deliveryultrasound contrast agentsphospholipid coatingligand distributioncholesterolacoustic responsemicrobubblelipid phasedialysisammoniaintoxicationcyanocobalaminvitamin B12atopic dermatitispsoriasistransferosomeslipid vesiclesskin topical deliveryoligonucleotideself-emulsifying drug delivery systemshydrophobic ion pairingintestinal permeation enhancersCaco-2 monolayerclarithromycinsolid lipid nanoparticlesoptimizationpermeationpharmacokineticsfollicular targetingdexamethasonealopecia areatalipomerslipid polymer hybrid nanocapsulesbiodistributionskinethyl celluloseTechnology: general issuesSilva Ana Catarinaedt1301848Sousa Lobo José ManueledtSilva Ana CatarinaothSousa Lobo José ManuelothBOOK9910557544303321Preclinical Evaluation of Lipid-Based Nanosystems3030940UNINA